{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013401","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.565004+00:00","generated_at":"2026-06-24T00:16:34.775499+00:00","sec_items":["1.01","2.02","2.05","3.03","5.02","5.03","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce","bullets":["Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).","Full-year 2022 revenue guidance reduced to at least $17.0M (from prior higher outlook); expects 3-5 system placements in H2.","Implements restructuring: 20% workforce reduction, $1.5M charge in Q3, expected $8-9M annualized cost savings.","CCO Andy Keys departs; CEO Robert Spignesi assumes commercial leadership.","Board launches strategic alternatives review; rejects Kennedy Lewis $5.00/share acquisition proposal."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013401","json":"https://secwatch.observer/filing/0001558370-22-013401.json","markdown":"https://secwatch.observer/filing/0001558370-22-013401.md","text":"https://secwatch.observer/filing/0001558370-22-013401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000155837022013401/0001558370-22-013401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000155837022013401/rpid-20220811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:16:34.775499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"398ec13340","claim":"Richard Keys resigned as Chief Commercial Officer at RAPID MICRO BIOSYSTEMS, INC..","evidence_excerpt":"Mr. Keys’ last date of employment with the Company as its Chief Commercial Officer was August 11, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000155837022013401/0001558370-22-013401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}